FDA Grants Breakthrough Therapy Designation to Bispecific Antibody for Follicular Lymphoma
November 27th 2023AbbVie and Genmab will share commercial responsibilities in the United States and Japan for epcoritamab-bysp (Epkinly) for the treatment of adults with follicular lymphoma that is relapsed or refractory following treatment with two or more therapies.